MONEY20/20
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands.
Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper and Deeploy, alongside executives from the world of cryptocurrency including Kraken and Fireblocks. Nvidia and AWS are back again co-hosting a summit with Money20/20 deep diving into AI.
Scarlett Sieber, Money20/20's Chief Strategy & Growth Officer, emphasised the significance of this year's theme, saying, "I’m delighted to welcome such esteemed powerhouses in the world of finance to what promises to be our biggest and most impactful show in Europe yet. As I will discuss with Former French President François Hollande in our fireside chat, Human X Machine encapsulates the essence of our rapidly evolving financial landscape and underscores the critical intersection of human ingenuity and artificial intelligence in shaping our financial future. The power of the Money20/20 platform is that the collective ecosystem of money at the most senior level comes together to have active discussions on the most important topics, breaking news, and work together to pave the way for a more resilient and inclusive financial ecosystem.”
Pav Gill, the Wirecard whistleblower, and one of Money20/20 Europe’s keynote speakers said, "Speaking at Money20/20 Europe is more than an opportunity; it's a reflection of a journey that took me from the heart of the Wirecard scandal to the helm of Confide. Unveiling one of finance's largest deceptions wasn't just about exposing truths; it was about sparking change. At Confide, we're building the future of business integrity, using technology to ensure that the lessons learned from Wirecard and the many other scandals pave the way for a more accountable and transparent industry. I look forward to sharing this mission and inspiring action towards a culture where ethics and technology intersect to create safer business environments for all.”
Sessions at Money20/20 Europe will revolve around five key topic areas within the show’s Human X Machine theme. They are as follows:
- A Customer Universe of One: Finance is becoming a Universe of One; A place where hyper-personalisation occurs at a microscopic level across every touchpoint.
- The Age of Atomic Finance: The Universe of One is made possible by monumental technological advancements, from artificial intelligence and cryptography to quantum computing. These leaps in technology have delivered atomic-level precision, unlocking the potential for a Universe of One.
- Meet the Architects: From the leaders of trailblazing startups to changemakers in agile incumbents, we’ll showcase the architects of the new dawn; the visionaries who create new landscapes for our financial futures.
- Signal Vs Noise: The pace of financial innovation continues accelerating, fueled by emerging technologies like AI, blockchain, and Web3. Yet visionary breakthroughs live alongside hype-driven tangents. We need voices committed to elevating discourse and realising technology’s potential through innovation geared towards progress.
- The Business of Money: Hear from founders, key decision makers, consultants, investors, and disruptors. We’ll delve into the actions that led to success, and just as crucially we’ll carry out an audit on the activities that produced undesirable outcomes.
The Money20/20 Europe agenda can be found here, while the lineup of confirmed speakers can be found here.
Media who would like to attend Money20/20 Europe can register for a complimentary press pass here.
About Money20/20
Launched by industry insiders in 2012, Money20/20 has rapidly become the heartbeat of the global fintech ecosystem. Over the last decade, the most innovative, fast-moving ideas and companies have driven their growth on our platform. Mastercard, Airwallex, J.P. Morgan, SHIELD, GCash, Stripe, Google, Marqeta, VISA, Adyen, Checkout.com and more make transformational deals and raise their global profile with us. Money20/20 attracts leaders from the world’s greatest VC firms, banks, regulators and media platforms: convening to cut industry-shaping deals, build world-changing partnerships and unlock future-defining opportunities in Bangkok (23-25 April 2024), Amsterdam (4-6 June 2024) and Las Vegas (27-30 October 2024). Money20/20 also recently launched Twentyfold, a Digital Intelligence product containing the deepest and widest repository of fintech startup data in the world. Money20/20 is where the world’s fintech leaders convene to grow their businesses. Money20/20 is part of Ascential plc. Follow Money20/20 on X and LinkedIn for show developments and updates. We’re Where Money Does Business.
Follow Money20/20 on Twitter for show developments and updates.
You can also find us on LinkedIn at Money20/20.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416620432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom